{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:21:49Z","timestamp":1793845309489,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2022.11.027","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:04:38Z","timestamp":1669295078000},"page":"2605-2614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Anaphylaxis: Revision of the Brighton collaboration case definition"],"prefix":"10.1016","volume":"41","author":[{"given":"Michael S.","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda","family":"Amarasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kelso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Yu-Hor Thong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina A.","family":"Top","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.vaccine.2022.11.027_b0005","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.027_b0010","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990\u20132016","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.11.027_b0015","doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:125-9. https:\/\/doi.org\/10.15585\/mmwr.mm7004e1.","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"10.1016\/j.vaccine.2022.11.027_b0020","doi-asserted-by":"crossref","unstructured":"Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw Open. 2021;4:e2125524. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.25524.","DOI":"10.1001\/jamanetworkopen.2021.25524"},{"key":"10.1016\/j.vaccine.2022.11.027_b0025","doi-asserted-by":"crossref","unstructured":"Rasmussen TH, Mortz CG, Georgsen TK, Rasmussen HM, Kjaer HF, Bindslev-Jensen C. Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up. Clin Transl Allergy. 2021;11:e12044. .","DOI":"10.1002\/clt2.12044"},{"issue":"11","key":"10.1016\/j.vaccine.2022.11.027_b0030","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40264-021-01104-9","article-title":"Cumulative adverse event reporting of anaphylaxis after mRNA COVID-19 vaccine (Pfizer-BioNTech) injections in Japan: the first-month report","volume":"44","author":"Iguchi","year":"2021","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.vaccine.2022.11.027_b0035","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"14","key":"10.1016\/j.vaccine.2022.11.027_b0040","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2022.11.027_b0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2013Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.11.027_b0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40413-016-0120-5","article-title":"International Consensus (ICON): allergic reactions to vaccines","volume":"9","author":"Dreskin","year":"2016","journal-title":"World Allergy Organ J"},{"issue":"10","key":"10.1016\/j.vaccine.2022.11.027_b0055","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"issue":"5-6","key":"10.1016\/j.vaccine.2022.11.027_b0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0264-410X(03)00511-5","article-title":"Standardized case definitions of adverse events following immunization (AEFI)","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.027_b0065","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.jaip.2021.04.025","article-title":"Ascertainment bias in anaphylaxis safety data of COVID-19 vaccines","volume":"9","author":"Hourihane","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2022.11.027_b0070","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1016\/j.jaip.2021.06.035","article-title":"Vaccine hesitancy: drivers and how the allergy community can help","volume":"9","author":"Turner","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2022.11.027_b0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.anai.2022.01.016","article-title":"We should abandon the Brighton Collaboration criteria for vaccine-associated anaphylaxis","volume":"129","author":"Hurley","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2022.11.027_b0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.anai.2021.03.024","article-title":"Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines","volume":"127","author":"Kelso","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2022.11.027_b0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.anai.2022.01.040","article-title":"We should not abandon the Brighton Collaboration criteria for vaccine-associated anaphylaxis","volume":"129","author":"Blumenthal","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2022.11.027_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836222","article-title":"Pathophysiological, cellular, and molecular events of the vascular system in anaphylaxis","volume":"13","author":"Nu\u00f1ez-Borque","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.11.027_b0095","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jaip.2019.01.059","article-title":"Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism","volume":"7","author":"Giavina-Bianchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2022.11.027_b0100","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1111\/all.14794","article-title":"Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation","volume":"76","author":"Klimek","year":"2021","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.vaccine.2022.11.027_b0105","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.jaip.2021.03.011","article-title":"Use and interpretation of acute and baseline tryptase in perioperative hypersensitivity and anaphylaxis","volume":"9","author":"Vitte","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.vaccine.2022.11.027_b0110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/all.12475","article-title":"First European data from the network of severe allergic reactions (NORA)","volume":"69","author":"Worm","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.vaccine.2022.11.027_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.iac.2021.09.010","article-title":"Anaphylaxis: Epidemiology and differential diagnosis","volume":"42","author":"Motosue","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"10.1016\/j.vaccine.2022.11.027_b0120","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.anai.2018.07.017","article-title":"The changing face of anaphylaxis in adults and adolescents","volume":"121","author":"Pattanaik","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2022.11.027_b0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: Initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2022.11.027_b0130","doi-asserted-by":"crossref","unstructured":"Cornelius VR, Liu K, Peacock J, Sauzet O. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. BMJ Open. 2016;6:e010599. https:\/\/doi.org\/10.1136\/bmjopen-2015-010599.","DOI":"10.1136\/bmjopen-2015-010599"},{"issue":"4","key":"10.1016\/j.vaccine.2022.11.027_b0135","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2022.11.027_b0140","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cea.12418","article-title":"Epidemiology of anaphylaxis","volume":"45","author":"Tejedor Alonso","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"15","key":"10.1016\/j.vaccine.2022.11.027_b0145","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA COVID-19 vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.11.027_b0150","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.vaccine.2022.11.027_b0155","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.vaccine.2020.02.046","article-title":"Immunization stress-related response - Redefining immunization anxiety-related reaction as an adverse event following immunization","volume":"38","author":"Gold","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.027_b0160","unstructured":"World Health Organization. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. 2019. Last accessed 12 August 2022; Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241515948."},{"issue":"4","key":"10.1016\/j.vaccine.2022.11.027_b0165","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamainternmed.2021.8515","article-title":"Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis","volume":"182","author":"Chu","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2022.11.027_b0170","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jaip.2022.02.025","article-title":"Vocal cord dysfunction\/inducible laryngeal obstruction(s) mimicking anaphylaxis during SARS-CoV-2 (COVID-19) vaccination","volume":"10","author":"Leong","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2022.11.027_b0175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.11.027_b0180","unstructured":"World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd ed., 2019 update. 2021. Last accessed 13 August 2022; Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241516990."},{"key":"10.1016\/j.vaccine.2022.11.027_b0185","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12887-016-0633-7","article-title":"Blood pressure percentile charts to identify high or low blood pressure in children","volume":"16","author":"Banker","year":"2016","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.vaccine.2022.11.027_b0190","unstructured":"National Heart LaBI. Low blood pressure. 2022. Last accessed 29 August 2022; Available from: https:\/\/www.nhlbi.nih.gov\/health\/low-blood-pressure."},{"key":"10.1016\/j.vaccine.2022.11.027_b0195","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2019.00494","article-title":"Biomarkers in human anaphylaxis: A critical appraisal of current evidence and perspectives","volume":"10","author":"Beck","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.11.027_b0200","doi-asserted-by":"crossref","unstructured":"Lee AYS. Elevated Serum Tryptase in Non-Anaphylaxis Cases: A Concise Review. Int Arch Allergy Immunol. 2020;181(5):357-364. doi: https:\/\/doi.org\/10.1159\/000506199. Epub 2020 Mar 3. PMID: 32126554.","DOI":"10.1159\/000506199"},{"key":"10.1016\/j.vaccine.2022.11.027_b0205","unstructured":"Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, et al. The Brighton Collaboration: Creating a global standard for case definitions (and guidelines) for adverse events following immunization. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005."},{"key":"10.1016\/j.vaccine.2022.11.027_b0210","unstructured":"https:\/\/www.gov.uk\/government\/news\/confirmation-of-guidance-to-vaccination-centres-on-managing-allergic-reactions-following-covid-19-vaccination-with-the-pfizer-biontech-vaccine (accessed 11th October 2022)."},{"key":"10.1016\/j.vaccine.2022.11.027_b0215","doi-asserted-by":"crossref","unstructured":"Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B. Can the Brighton Collaboration case definitions be used to improve the quality of adverse event following immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine. 2010;28:4487-98. https:\/\/doi.org\/10.1016\/j.vaccine.2010.04.041.","DOI":"10.1016\/j.vaccine.2010.04.041"},{"key":"10.1016\/j.vaccine.2022.11.027_b0220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/11318970-000000000-00000","article-title":"Diagnostic utility of two case definitions for anaphylaxis: a comparison using a retrospective case notes analysis in the UK","volume":"33","author":"Erlewyn-Lajeunesse","year":"2010","journal-title":"Drug Saf"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22014256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22014256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:22Z","timestamp":1759404442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22014256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":44,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X22014256"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anaphylaxis: Revision of the Brighton collaboration case definition","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}